Nektar Therapeutics

NKTR · NasdaqCM · Stock · Healthcare

$36.89

-2.72% today

Delayed price, 2026-10-15 08:55 UTC

What Nektar Therapeutics does

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Key facts

Sector

Healthcare

Industry

Biotechnology

Market cap

$1.26B

P/E (ttm)

—

Forward P/E

-3.6

Dividend yield

0.00%

Beta

1.27

Profit margin

-287.8%

Employees

Headquarters

San Francisco, CA, United States

Exchange

NasdaqCM

Website

www.nektar.com

Performance

1 Month

-45.0%

3 Months

-46.0%

6 Months

-56.5%

1 Year

-36.1%

5 Years

-78.2%

$33.4052-week range$109.00

Biggest setback — last 12 months

-59.8%

20 Apr 2026 → 12 Oct 2026

Fell from $91.68 to $36.89 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+149.1%

2 Feb 2026 → 20 Apr 2026

Ran from $36.81 to $91.68 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▼ Trend: Downtrend

Price is below its 20-, 50- and 200-day averages, each stacked below the next — a classic technical downtrend structure.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$29.68 (-19.5%)	$36.89	$45.85 (+24.3%)
3 Months	$25.31 (-31.4%)	$36.89	$53.77 (+45.8%)
6 Months	$21.65 (-41.3%)	$36.89	$62.85 (+70.4%)
12 Months	$17.36 (-52.9%)	$36.89	$78.37 (+112.4%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 75.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

XERS

Xeris Biopharma Holdings, Inc.

$9.77 · -4.2%

PCRX

Pacira BioSciences, Inc.

$36.40 · +0.3%

RAPP

Rapport Therapeutics, Inc.

Amphastar Pharmaceuticals, Inc.

$26.08 · +0.1%

Recent insider activity

Acquired 2,000 shares — WHITFIELD ROY A, Director · 2026-09-25

Acquired 2,000 shares — GREER R SCOTT, Director · 2026-09-25

Acquired 2,000 shares — CHESS ROBERT, Director · 2026-09-25

Acquired 2,000 shares — Brainard Diana, Director · 2026-09-25

Acquired 2,000 shares — Ajer Jeffrey Robert, Director · 2026-09-25

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.